These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7942168)

  • 21. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism.
    Rauch F; Plotkin H; Travers R; Zeitlin L; Glorieux FH
    J Clin Endocrinol Metab; 2003 Mar; 88(3):986-92. PubMed ID: 12629073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Biochemical markers of bone turnover. New aspect. Metabolic bone markers in osteogenesis imperfecta].
    Tanaka H
    Clin Calcium; 2009 Aug; 19(8):1142-7. PubMed ID: 19638698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impaired pyridinoline cross-link formation in patients with osteogenesis imperfecta.
    Hasegawa K; Kataoka K; Inoue M; Seino Y; Morishima T; Tanaka H
    J Bone Miner Metab; 2008; 26(4):394-9. PubMed ID: 18600407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations.
    Roschger P; Fratzl-Zelman N; Misof BM; Glorieux FH; Klaushofer K; Rauch F
    Calcif Tissue Int; 2008 Apr; 82(4):263-70. PubMed ID: 18311573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI.
    Semler O; Netzer C; Hoyer-Kuhn H; Becker J; Eysel P; Schoenau E
    J Musculoskelet Neuronal Interact; 2012 Sep; 12(3):183-8. PubMed ID: 22947550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unique micro- and nano-scale mineralization pattern of human osteogenesis imperfecta type VI bone.
    Fratzl-Zelman N; Schmidt I; Roschger P; Roschger A; Glorieux FH; Klaushofer K; Wagermaier W; Rauch F; Fratzl P
    Bone; 2015 Apr; 73():233-41. PubMed ID: 25554599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Collagen-derived markers of bone metabolism in osteogenesis imperfecta.
    Lund AM; Hansen M; Kollerup G; Juul A; Teisner B; Skovby F
    Acta Paediatr; 1998 Nov; 87(11):1131-7. PubMed ID: 9846914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices.
    Woitge HW; Pecherstorfer M; Li Y; Keck AV; Horn E; Ziegler R; Seibel MJ
    J Bone Miner Res; 1999 May; 14(5):792-801. PubMed ID: 10320528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats.
    DeLaurier A; Jackson B; Pfeiffer D; Ingham K; Horton MA; Price JS
    Res Vet Sci; 2004 Aug; 77(1):29-39. PubMed ID: 15120950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Excretion of collagen derived peptides is increased in women with stress urinary incontinence.
    Kushner L; Mathrubutham M; Burney T; Greenwald R; Badlani G
    Neurourol Urodyn; 2004; 23(3):198-203. PubMed ID: 15098214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Collagen crosslinks and mineral crystallinity in bone of patients with osteogenesis imperfecta.
    Vetter U; Weis MA; Mörike M; Eanes ED; Eyre DR
    J Bone Miner Res; 1993 Feb; 8(2):133-7. PubMed ID: 8442432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda.
    Baron R; Gertner JM; Lang R; Vignery A
    Pediatr Res; 1983 Mar; 17(3):204-7. PubMed ID: 6835724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone resorption is induced on the second day of bed rest: results of a controlled crossover trial.
    Baecker N; Tomic A; Mika C; Gotzmann A; Platen P; Gerzer R; Heer M
    J Appl Physiol (1985); 2003 Sep; 95(3):977-82. PubMed ID: 12909597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors and correlates of vitamin D status in children and adolescents with osteogenesis imperfecta.
    Edouard T; Glorieux FH; Rauch F
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3193-8. PubMed ID: 21832107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary type I collagen cross-linked N-telopeptides in inhabitants 18 years after cessation of exposure to cadmium in Japan.
    Omote S; Kido T; Nishijo M; Nakagawa H; Suwazono Y; Kobayashi E; Nogawa N
    Bull Environ Contam Toxicol; 2006 Feb; 76(2):187-94. PubMed ID: 16467995
    [No Abstract]   [Full Text] [Related]  

  • 36. Osteogenesis imperfecta after the menopause.
    Paterson CR; McAllion S; Stellman JL
    N Engl J Med; 1984 Jun; 310(26):1694-6. PubMed ID: 6727948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased cartilage type II collagen degradation in patients with osteogenesis imperfecta used as a human model of bone type I collagen alterations.
    Rousseau JC; Chevrel G; Schott AM; Garnero P
    Bone; 2010 Apr; 46(4):897-900. PubMed ID: 20005316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary N-telopeptides of type I collagen in healthy children.
    Sato J; Hasegawa K; Tanaka H; Morishima T
    Pediatr Int; 2010 Jun; 52(3):398-401. PubMed ID: 20113422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The functional muscle-bone unit in patients with osteogenesis imperfecta type I.
    Veilleux LN; Pouliot-Laforte A; Lemay M; Cheung MS; Glorieux FH; Rauch F
    Bone; 2015 Oct; 79():52-7. PubMed ID: 26004918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.